Sellas To Present SLS009 Data At American Society of Hematology – Initial Results Of Therapy In Newly Diagnosed AML Patients Expected In Q4
The Phase 2 study evaluated SLS009 alongside Azacitidine and Venetoclax in 62 patients with AML.
The Phase 2 study evaluated SLS009 alongside Azacitidine and Venetoclax in 62 patients with AML.